Cyborg Beetles Could Be Unlikely Heroes in Future Disaster Rescues
Researchers have made major strides in cyborg technology, creating a breed of cyborg beetles that can climb walls, obstacles, and sloped surfaces while being remotely guided by a video game controller.
Called "ZoBorgs," the cyborg beetles are a collaborative effort between The University of Queensland and the University of New South Wales, both in Australia, and Singapore's Nanyang Technological University.
To imbue their darkling beetles (Zophobas morio) with remote control, the researchers equipped them with a microchip backpack that sends electrical signals to the beetles' antennae or forewings (elytra), prompting them to move in different directions.
Related:
Darkling beetles are also known as 'superworms' for the worm-like form of their larvae. These creatures may help the world in multiple ways. Culinarily, they're a rich source of fatty acids and protein, commonly consumed in countries like Mexico and Thailand.
The larvae also love dining on one of the world's most prevalent plastics, polystyrene, which is used to make common conveniences like packing materials and disposable cutlery. This is not good for the beetles, but copying how they digest the substance could help us tackle the plastic waste problem.
At up to 32 millimeters (1.26 inches) in body length and about 8 millimeters (0.3 inches) in height, darkling beetles are small and nimble, possessing natural gifts that allow them to maneuver where robots cannot: within the tight confines of dense, jumbled rubble.
Featured in Advanced Science, the new study harnesses the beetles' natural gifts and "adds programmable controls that allow for precise directional guidance, without affecting the lifespan of the beetle," says engineer Thang Vo-Doan of the School of Mechanical and Mining Engineering at The University of Queensland.
These programmable controls are transmitted via a beetle-backpack with electrodes that act like electrical reins. Stimulating the antennae causes the beetle to turn, decelerate, or walk backwards. Stimulating both elytra causes acceleration or forward walking, while stimulating a single elytron causes sideways movement.
As a result, the ZoBorgs can cross obstacles equal to their body height with a success rate of 92 percent. They can also move from horizontal to vertical surfaces with a 71.2 percent success rate – a rate unmatched by previous cyborg insects or robots.
Lachlan Fitzgerald, an engineer at The University of Queensland, explains that while "robots at this scale have made strides in locomotion, the transition from horizontal surfaces to walls remains a formidable challenge for them." But not so for the ZoBorgs.
Plus, using beetles means that researchers do not have to design actuators, sensors, or control systems – the beetles are already naturally equipped by many millions of years of evolutionary adaptations. These climbing adaptations include flexible, adhesive footpads, gripping claws, and rigid but agile body structures.
In combination with their antennae, insects use sensors in their legs and mechanoreceptors in their exoskeletons to sense physical stimuli, such as surface textures and vibrations.
Future advances may focus on improving the beetles' climbing ability and autonomy by incorporating an inertial measurement unit (IMU) that provides real-time, non-visual data like acceleration and other forces.
The addition of a compact, lightweight visual camera can further boost control mechanisms, and will be necessary for identifying trapped individuals in search and rescue situations. Finally, cyborg advances described here could inspire innovations in robotics, such as the incorporation of beetle-like feelers to improve robots' navigational abilities.
Notably, scientists maintained ethical practices to ensure the beetles' well-being. Compared to other animals used in research, the beetles lived in relatively ritzy conditions, sleeping on wheat-bran bedding and eating fresh apple slices. Following the experiments, they received care for the remainder of their three-month lifespans.
This study demonstrates that cyborg science is making essential strides. It may not yet be the robotic organs promised by science fiction, but a cyborg beetle may be just as likely to save lives.
This research is published in Advanced Science.
Quantum Breakthrough Could Make Your Devices 1,000 Times Faster
New Viral Indie Rock Sensation Reveals They're 100% AI
ChatGPT: 5 Surprising Truths About How AI Chatbots Actually Work
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
33 minutes ago
- Fox News
Men face double dementia risk if they have a hidden genetic mutation
A hidden genetic mutation could predict a man's likelihood of developing dementia. That's according to an Australian study led by Monash and Curtin Universities, which analyzed the medical data of thousands of Australians and Americans. Men who had a certain variant in the haemochromatosis (HFE) gene — which regulates iron levels in the body — were found to be at a higher risk of dementia, the researchers found. Previously healthy men over age 70 who have two copies of the variant, which is known as H63D, are at least twice — or up to four times — as likely to develop dementia. Having just one copy did not appear to elevate the risk. One in 36 men carry two copies of the mutation; one in three have just a single copy. "It is only men who have two copies of the variant that are at risk," study co-author Professor John Olynyk from the Curtin Medical School told Fox News Digital. "Women are not affected by the abnormality – we do not know why that is at the current point in time." The study, which was published in the journal Neurology, used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, which gathered health and aging data for 19,114 healthy older adults. Those who have the genetic variant can't change it, but it's possible that the "brain pathways" it affects could be treated, Olynyk noted. "The HFE gene is routinely tested for in most Western countries … when assessing people for haemochromatosis, a disorder that causes the body to absorb too much iron," the doctor said. "Our findings suggest that perhaps this testing could be offered to men more broadly." Despite the fact that the HFE gene is responsible for controlling iron levels, the team found no direct link between iron and dementia risk. "Our findings suggest that perhaps this testing could be offered to men more broadly." "This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body," Olynyk added. More research is needed to determine why the heightened risk wasn't seen in women. "Understanding why men with the double H63D variant are at higher risk could pave the way for more personalized approaches to prevention and treatment," added co-author Professor Paul Lacaze from Monash University in a press release. The main limitation of the study, according to Olynyk, was that the study population was largely composed of Australians. "Whether other populations exhibit the same effects is unclear," he told Fox News Digital. "Our work should be repeated in different countries to assess this." "Further research will be undertaken to try and determine the likely mechanism by which this anomaly causes dementia and what more we can do to reduce the impact of it." Beyond this specific mutation, many other genetic and environmental factors can contribute to dementia risk, Olynyk noted. "While genetic risk factors cannot be changed, the mechanisms by which these genetic abnormalities and environmental factors cause disease may well be modifiable to some extent, through adopting a healthy lifestyle and being proactive about maintaining an overall good state of health," he said. To reduce risk, the researchers recommend adopting a healthy lifestyle that includes exercising regularly, eating a nutritious diet, minimizing alcohol intake, remaining mentally active, and seeing a doctor to address any medical problem known to increase the likelihood of dementia. For more Health articles, visit The University of Melbourne, The Royal Children's Hospital, Murdoch Children's Research Institute and Fiona Stanley Hospital also contributed to the study.
Forbes
2 hours ago
- Forbes
Earth's Oldest Impact Crater May Be Far Younger Than Thought
A satellite image of Gosses Bluff Crater located near the center of Australia. The crater is ... More believed to have been created by an asteroid impact around 142 million years ago. In March 2025, researchers from the Curtins School of Earth and Planetary Sciences and the Geological Survey of Western Australia announced the discovery of Earth's oldest impact crater, located in the very heart of the Pilbara region of Western Australia. Based on their field investigations, the crater formed about 3.5 billion years ago, making it the oldest known by more than a billion years — the previous record holder being the Vredefort structure in South Africa. However, a new study challenges the initial findings by reassessing the age of the impact crater. As study authors Aaron J. Cavosie, Professor for Earth and Planetary Sciences, Curtin University, and Alec R. Brenner, Postdoc at Yale University, write for the online magazine The Conversation, they discovered geological evidence suggesting the impact happened almost one billion years later than previously thought. Both studies mapped the distribution of shatter cones, cone-shaped branching structures forming at the moment of impact, when shock waves shatter the bedrock. Example of shatter cones preserved in limestone. The first study discovered shatter cones in 3.47 billion year-old sediment layers, deducing that the impact happened over 3 billion years ago. However, a more recent field survey discovered shatter cones also in lava covering the sediment layers, and therefore of younger age. The impact had to occur after the formation of the youngest rocks that contained shatter cones, meaning sometime after the 2.77-billion-year-old lavas. The authors of the new study also propose to name the crater 'Miralga impact structure," after the Aboriginal name of the region. The study," Geology and Mars analog potential of the <2.7-billion-year-old Miralga impact structure, North Pole Dome, Pilbara Craton, Australia," was published in the journal Science Advances.
Medscape
11 hours ago
- Medscape
New Clozapine Consensus Guidelines Drop ANC Monitoring
Monitoring absolute neutrophil count (ANC) levels beyond 2 years of clozapine treatment is no longer necessary, new international guidelines stated. While low ANC levels — associated with severe neutropenia — pose a significant risk early in treatment, evidence shows that the risk drops substantially over time. Still, many patients continue to undergo routine blood tests well beyond the high-risk period, lead guideline author Dan Siskind, MD, PhD, professor of psychiatry, The University of Queensland, Brisbane, Australia, told Medscape Medical News. 'What we're saying is that after 2 years of monitoring, you can stop doing blood tests to monitor ANC levels, which is a massive change,' he added. The expert panel also provides detailed suggestions for monitoring other adverse drug reactions (ADRs) related to clozapine, including constipation and sialorrhea. And the group recommends an ANC of 1.0 × 109 cells/L as a threshold at which to consider stopping clozapine. The guidelines were published online on July 2, 2025 in Lancet Psychiatry . An Underutilized Treatment Clozapine is the only FDA-approved drug for treatment-resistant schizophrenia. An estimated 814,000 to 1.2 million Americans have this condition. Although clozapine is widely regarded as a superior antipsychotic, many clinicians remain hesitant to prescribe it due to concerns about ADRs — most notably, severe neutropenia, in which dangerously low neutrophil levels increase the risk for infection and even death. Despite estimates that 25%-30% of Americans with schizophrenia could benefit from clozapine, only about 4% receive it. The concern over severe neutropenia has led to stringent ANC monitoring protocols in some jurisdictions. Until recently, a risk evaluation and mitigation strategies (REMS) program in the US required physicians and pharmacists to provide documentation of a patient's ANC. However, after lobbying by relevant professional organizations including the American Psychiatric Association (APA), which argued the program poses unnecessary barriers to accessing a potentially life-saving medication, the FDA made the decision to discontinue the REMS program. Some experts insist the risk for severe neutropenia is low in patients taking clozapine. As previously reported by Medscape Medical News a study presented at the 2024 APA annual meeting showed the risk for moderate-to-severe neutropenia is low to minimal in patients with treatment-resistant schizophrenia. Siskind agreed. He points to other research showing the rate of severe neutropenia at initiation of clozapine is around 0.9%, but after peaking, the risk then 'drops over time' and after about 18 weeks, 'it's very low, and after about 2 years, it's negligible.' Yet patients who have been on clozapine for 10 years still receive blood tests every 4 weeks. 'We felt that's probably low value healthcare that creates impediments to people on clozapine,' said Siskind. No Current Consensus The guideline authors noted there's currently no international consensus on ANC thresholds for considering clozapine cessation. In some jurisdictions, an ANC of fewer than about 2.0 × 109 cells/L is the threshold but in other areas, the threshold is 1.5 × 109 cells/L. And when the REMS program was initiated, it set a lower ANC threshold (1.0 × 109 cells/L), which is in-line with that commonly used in hematology. 'What we're calling for is a global consensus; there should be one threshold,' said Siskind. Aside from neutropenia, there is a host of other clozapine-related ADRs, many of which are under-reported and some can be lethal. The consensus guidelines were developed using a global Delphi process. A steering committee — including a hematologist with expertise in clozapine-associated severe neutropenia — designed a questionnaire focused on ANC and ADR monitoring. The questionnaire was distributed to an international expert panel comprising psychiatrists and pharmacists. Recommendations were formulated based on their responses, with consensus defined as at least 75% agreement. The experts developed a clozapine monitoring algorithm that includes: Weekly ANC monitoring for the first 18 weeks after initiation Monthly monitoring from week 19 through year 2 Annual complete blood counts thereafter to screen for hematologic malignancies The algorithm includes a recommended ANC cessation threshold of 1.0 × 109 cells/L — or 0.5 × 109 cells/L for individuals with benign ethnic neutropenia who are Duffy antigen receptor for chemokines-null. In addition to clozapine, the new guidance advises clinicians to consider other potential causes of a low ANC, said Siskind. 'If it's 2 weeks after starting clozapine and there's a sudden, precipitous drop, it's likely related to the medication,' he explained. 'But if it's 18 months after initiation and you see a drop in neutrophil count, it's probably due to something else — and worth investigating.' Other causes of transient neutropenia could be chemotherapy treatment or a concomitant infection, he added. Side Effect Checklist Panel members developed a detailed checklist for regular and comprehensive ADR monitoring. The checklist includes pharmacological and nonpharmacological recommendations for each ADR where present. For example, in the category of constipation, which Siskind said is 'the number one cause of mortality' in patients taking clozapine, the experts suggest asking patients about bowel movement frequency and presence of blood and pain, and using the Bristol Stool Chart to determine if there's a health issue. Given the high prevalence of gastrointestinal hypomotility, prophylactic laxatives are recommended, the panel said. Sialorrhea occurs in up to 92% of patients taking clozapine and this can cause pneumonia, which is the second highest cause of death in people on clozapine, said Siskind. Here, the panel noted pharmacological strategies could include adding amisulpride or ipratropium sublingual spray while chewing sugar-free gum or placing a towel over the pillow when sleeping. Panel members also provided management guidelines for weight gain and metabolic syndrome, gastro-esophageal reflux, sedation, sleep apnea, nocturnal enuresis and urinary incontinence, and tachycardia. The panel stressed ADR monitoring should occur in partnership with primary care physicians. Annual ECGs did not reach consensus for routine use, so the expert panel does not recommend them. They concluded that cardiomyopathy in clozapine patients is more likely related to comorbidities such as obesity, diabetes, and tachycardia. Removing Barriers to an Optimal Treatment Commenting on the new guidance for Medscape Medical News , Frederick Nucifora Jr, PhD, DO, associate professor, Department of Psychiatry, Johns Hopkins School of Medicine, and director of the clozapine clinic at Johns Hopkins Bayview Medical Center, Baltimore, said it is sensible, reasonable, and could help remove 'troubling' barriers to accessing clozapine. He welcomed the ADR monitoring suggestions as clozapine-related side effects can be life-threatening and are the reason patients don't stay on the drug. 'There's so much confusion around using clozapine and the side effects and how to address them that people don't use the medicine, so it's very useful to have something to help guide us,' he said. He said it's deeply unfortunate that clozapine remains underused, particularly given its status as the most effective treatment available. In his experience, the drug has had a transformative impact on his patients. To increase physician comfort in prescribing clozapine, Nucifora suggests creating centers of excellence that could offer consultations on using the drug. Also commenting for Medscape Medical News , Mahavir Agarwal, MD, PhD, associate professor, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada who heads a clozapine clinic at the Centre for Addiction at Mental Health (CAMH), said the paper's 'mini flow chart' to manage side effects is a valuable tool for physicians to review with patients. He noted that the guideline authors are recognized leaders in the field and fully agrees that lifetime monitoring of ANC levels is likely unnecessary. Clozapine has had a huge impact on patients at the CAMH clinic, said Agarwal. 'Among our clientele are people who work full–time in very, very high-capacity roles; we have scientists, teachers, all manner of professions, who are able to lead meaningful lives after they found clozapine.' 'Other antipsychotics may do that, but the beauty of clozapine is that it can completely turn life around for somebody who has not responded to other antipsychotics.'
